The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.

Fusion Antibodies Plc


Offer details
Expected size of offer (M): TBC
Expected first date of trading: 20/12/2017
Market: AIM
Location of address at which admission document will be available: Copies of the admission document, which will contain full details about the applicant and the admission of its securities, will be available from the company's website, www.fusionantibodies.com.
Date at which admission document will be available: 20/12/2017

Advisors
Sponsor: -
Nominated Advisor (AIM Companies): Allenby Capital Limited
Nominated Broker (AIM Companies): Allenby Capital Limited

Company details
Name Role
Dr Simon Gordon Douglas Chairman
Dr Paul Gerard Kerr Chief Executive Officer
James Alexander Fair Chief Financial Officer
Dr Richard John Buick Chief Technical Officer
Sonya Maria Ferguson Senior Independent Director
Dr Alan Mawson Non-Executive Director
Colin James Walsh Non-Executive Director
Timothy William Watts Proposed Non-Executive Director

Facts and Figures
Fiscal year end: 31 March
Incorporated in: Northern Ireland
Website URL: www.fusionantibodies.com
space
Description of business:
Fusion Antibodies plc (the "Company") is a Belfast based contract research organisation providing services to biopharmaceutical and diagnostics companies that are involved in the development of antibodies for both therapeutic drug and diagnostic applications. The Company provides a broad range of services in antibody generation, development, production, characterisation and optimisation. T...

Person(s) interested:
Before admission: Shareholder % Crescent Capital II LP(1) 17.24 Viridian Growth Fund LP(2) 11.91 Jim Johnston 8.56 Invest Northern Ireland(3) 6.33 Sir John Cadogan 5.55 QUBIS Limited 4.61 Michael Townsley 3.92 Dr Paul Kerr 3.46 Patrick Johnston estate 3.36 Dr Richard Buick 3.33 (1) Managed by Crescent Capital NI Limited ("Crescent Capital"). Colin Walsh is the chief executive and founder of Crescent Capital. (2) Managed by Clarendon Fund Managers Limited ("Clarendon"). Alan Mawson is a non-executive director of Clarendon and sits on its investment committee. Clarendon is also the fund manager of Nitech Growth Fund LP, which holds 2.33% of the share capital of the Company before admission. (3) In addition to the 6.33% of shares directly by Invest Northern Ireland, Invest Northern Ireland is also indirectly interested in the Ordinary Shares held by Crescent Capital II LP and Nitech Growth Fund LP. After admission: TBC Shareholder % Crescent Capital II LP(1) 17.24 Viridian Growth Fund LP(2) 11.91 Jim Johnston 8.56 Invest Northern Ireland(3) 6.33 Sir John Cadogan 5.55 QUBIS Limited 4.61 Michael Townsley 3.92 Dr Paul Kerr 3.46 Patrick Johnston estate 3.36 Dr Richard Buick 3.33 (1) Managed by Crescent Capital NI Limited ("Crescent Capital"). Colin Walsh is the chief executive and founder of Crescent Capital. (2) Managed by Clarendon Fund Managers Limited ("Clarendon"). Alan Mawson is a non-executive director of Clarendon and sits on its investment committee. Clarendon is also the fund manager of Nitech Growth Fund LP, which holds 2.33% of the share capital of the Company before admission. (3) In addition to the 6.33% of shares directly by Invest Northern Ireland, Invest Northern Ireland is also indirectly interested in the Ordinary Shares held by Crescent Capital II LP and Nitech Growth Fund LP. After admission: TBC


Fusion Antibodies Plc

Related links

Further informations about 7 and 7/30 days issues can be find by clicking on one of the options below:

Issues last 7 days

Last issues 7/30 days

Back to New and recent issues - Home



The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds